Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) Return on Equity (2023 - 2025)

NewAmsterdam Pharma's Return on Equity history spans 3 years, with the latest figure at 0.08% for Q4 2025.

  • For Q4 2025, Return on Equity rose 34.0% year-over-year to 0.08%; the TTM value through Dec 2025 reached 0.08%, up 34.0%, while the annual FY2025 figure was 0.08%, 38.0% up from the prior year.
  • Return on Equity for Q4 2025 was 0.08% at NewAmsterdam Pharma, up from 0.29% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.08% in Q4 2025 and bottomed at 0.46% in Q1 2024.
  • The 3-year median for Return on Equity is 0.34% (2024), against an average of 0.32%.
  • The largest annual shift saw Return on Equity dropped -8bps in 2024 before it skyrocketed 34bps in 2025.
  • A 3-year view of Return on Equity shows it stood at 0.35% in 2023, then dropped by -23bps to 0.43% in 2024, then surged by 81bps to 0.08% in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Return on Equity are 0.08% (Q4 2025), 0.29% (Q3 2025), and 0.21% (Q2 2025).